VB18214 / Shenzhen Yangli Pharma - LARVOL DELTA

Discovery of a novel and selective CDK2 inhibitor for targeted cancer therapy (AACR 2025) - "Compared to the clinically advanced CDK2 inhibitor PF-07104091, VB18214 demonstrated 5-fold greater potency in inhibiting CDK2 kinase activity, 16-fold higher affinity for CDK2 in NanoBRET assays, 2-fold greater selectivity over CDK1 in both biochemical and intracellular assays, and 9-fold higher antiproliferative activity in OVCAR3 cells.These findings position VB18214 as a potent and selective CDK2 inhibitor with significant potential for clinical development in cancers driven by CDK2/cyclin E dysregulation, as well as CDK4/6 treatment progressed mBC. More characterization data for VB18214 will be updated at the meeting."

Breast Cancer • Oncology • Ovarian Cancer • Solid Tumor • CCNB1 • CCND1 • CCND3 • CCNE1 • CDK1 • CDK6 • CDK7 • CDK9